RNA Avidity Biosciences
- 37.610
- -0.720-1.88%
- 36.860
- -0.750-1.99%
Avidity Biosciences News
(RNA) - Analyzing Avidity Biosciences's Short Interest
Avidity Biosciences's (NYSE:RNA) short percent of float has fallen 4.33% since its last report. The company recently reported that it has 10.82 million shares sold short, which is 14.81% of all regula
Estimating The Intrinsic Value Of Avidity Biosciences, Inc. (NASDAQ:RNA)
Avidity Biosciences, Inc. Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
SAN DIEGO, June 17, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide C
Avidity Biosciences And CleanSpark Were Among The 10 Biggest Mid-Cap Stock Gainers Last Week (June 9-June 15): Are These In Your Portfolio?
These mid-cap stocks were the best performers in the last week. Are they in your portfolio?Avidity Biosciences, Inc. (NASDAQ:RNA) shares jumped 50.15% following the announcement that the Phase 1/2 tri
Avidity Biosciences(RNA.US) Officer Sells US$3.72 Million in Common Stock
$Avidity Biosciences(RNA.US)$ Officer MacLean Michael F sold 104.25K shares of common stock on Jun 12, 2024 at an average price of $35.7153 for a total value of $3.72 million.Source: Announcement What
Avidity Biosciences(RNA.US) Director Sells US$3.81 Million in Common Stock
$Avidity Biosciences(RNA.US)$ Director LEVIN ARTHUR A sold 100K shares of common stock on Jun 12, 13, 2024 at an average price of $38.0741 for a total value of $3.81 million.Source: Announcement What
Avidity Biosciences(RNA.US) Officer Sells US$11.59 Million in Common Stock
$Avidity Biosciences(RNA.US)$ Officer Boyce Sarah sold 300K shares of common stock on Jun 12, 13, 14, 2024 at an average price of $38.6277 for a total value of $11.59 million.Source: Announcement What
Avidity Biosciences to Participate in Upcoming Investor Conference
SAN DIEGO, June 14, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide C
Wells Fargo Maintains Avidity Biosciences(RNA.US) With Buy Rating, Raises Target Price to $75
Wells Fargo analyst Yanan Zhu maintains $Avidity Biosciences(RNA.US)$ with a buy rating, and adjusts the target price from $50 to $75.According to TipRanks data, the analyst has a success rate of 46.1
Adobe, Avidity Biosciences And 3 Stocks To Watch Heading Into Friday
With U.S. stock futures trading mixed this morning on Friday, some of the stocks that may grab investor focus today are as follows:Adobe Inc. (NASDAQ:ADBE) posted upbeat results for its second quarter
Avidity Biosciences Raises $400M via Stock Offering
Express News | Avidity Biosciences Inc - Pricing of an Underwritten Public Offering of 10.55 Mln Shares of Its Common Stock at a Price to Public of $38.00 per Share
Reported Earlier, Avidity Biosciences Prices $400.9M Public Offering Of 10.55M Common Shares At $38/Share
All of the shares to be sold in the offering are to be sold by Avidity. The gross proceeds to Avidity from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be $400.9 million. The offering is expected to close on or about June 17, 2024, subject to the satisfaction of customary closing conditions
Express News | Avidity Biosciences, Inc. Announces Pricing of Public Offering of Common Stock
Form 144 | Avidity Biosciences(RNA.US) Director Proposes to Sell 2.3 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 13, $Avidity Biosciences(RNA.US)$ Director BUTLER-LEVIN REVOCABLE TRUST U/ADTD 05/27/2003 intends to sell 60,000 shares of its common stock on Jun 13, with a total market v
Avidity Biosciences Price Target Raised to $45.00/Share From $40.00 by B of A Securities
Avidity Biosciences Price Target Raised to $45.00/Share From $40.00 by B of A Securities
Calendar Of Equity Issues Expected To Price This Week
Initial Offerings: Sound Point Meridian Capital Inc. (SPMC)--3.75 million shares expected to price Thursday via Oppenheimer & Co Inc, B Riley Securities Inc, Janney Mo
A Quick Look at Today's Ratings for Avidity Biosciences(RNA.US), With a Forecast Between $45 to $56
On Jun 13, major Wall Street analysts update their ratings for $Avidity Biosciences(RNA.US)$, with price targets ranging from $45 to $56.BofA Securities analyst Geoff Meacham maintains with a buy rati
Express News | Avidity Biosciences Inc : BofA Global Research Raises Price Objective to $45 From $40
Express News | Avidity Biosciences Inc : Raymond James Raises Target Price to $90 From $66
Analysis
Price Target
No Data
